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Nanomedicine: A New Frontier in Cancer Therapeutics 
Pui Yan Lee and Kenneth K.Y. Wong* 
Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 
Abstract: Nanotechnology is a cutting edge and rapidly evolving technology in medicine. The potential of nanomedicine 
in cancer therapy is infinitely promising due to the fact that novel developments are constantly being explored. This is par-
ticularly the case in the use of nanoparticles in both tumor diagnosis, as well as treatment. This article will attempt to de-
scribe some recent advances using nanoparticle drug delivery system in cancer therapy. The evolution history, the chal-
lenges and the role of nanoparticles in cancer drug delivery will briefly be discussed together with additional opportunities 
in cancer therapy. An overall understanding of these issues will help with further advancement of designing better drug 
delivery system that can be applied clinically. 
Keywords: Nanotechnology, drug delivery, tumor therapy. 
INTRODUCTION 
 With more than one million new cases of cancer diag-
nosed in United states 2009 [1] and the fact that clinical out-
come of current cancer therapeutics using either radiotherapy 
or chemotherapy is far from optimal, the development of an 
effective cancer treatment is crucial. Furthermore, cancer 
patients require frequent hospital visits for chemotherapy 
care and often suffer from undesirable side effects. Efforts 
have thus been focused on the development of novel drug 
delivery systems for cancer therapy. 
 Nanotechnology is impacting positively in pharmaceutics 
and healthcare. Products in cosmetic and medicine consisting 
of nanoscale material have already been available in the 
market. Furthermore National Cancer Institute (NCI) has 
created an alliance with nanotechnology area in the hope to 
develop new breakthroughs in therapeutic and diagnostic 
modalities for cancer treatment. Numerous new generations 
of nanoparticles for therapeutic and diagnostic application 
have progressed to clinical trial stage in alliance with NCI. 
The funding allocated to nanotechnology has been increased 
to 1 billion in 2006 and predicted to reach 3.7 billion by 
2010 [2]. This advance is impossible to emerge without sub-
stantial basic knowledge of nanotechnology. The impact of 
nanotechnology is showing immense promise in improving 
the tumor therapeutic and diagnostic modalities. Due to the 
recent success, nanotechnology has received even more pub-
lic awareness based on its future potential to revolutionize 
development of clinical useful drug delivery system. 
EVOLUTION OF NANOMEDICINE 
 “Nanomedicine” is the application of nanotechnology 
into medicine. The evolution from the concept of “nano” to 
nanomedicine has taken a long journey. The concept of 
nanoscale was first coined by Richard Feynman [3]. His talk 
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in 1959 at a meeting of the American Physic Society titled 
“There’s plenty of room at the bottom” raised attention about 
the importance of controlling matter down to bottom atomic 
or molecular precision. His vision to suggest that manipula-
tion scaling down to atomic nanolevel (starting from the bot-
tom) inspired the eventual development for technology ad-
vancement. Although the concept of “nano” originated four 
decades back, the association with drug delivery and its ap-
plications in medicine has not been met with enormous en-
thusiasm until recently. Indeed, despite the fact that the basic 
discovery of many traditional drug delivery systems such as 
liposomes, polymeric micelles, nanoparticles, and dendrim-
ers was made in the 1960’s and 1970’s, these particles were 
only confirmed to be in the nanoparticle size range recently. 
Dating back to more than 150 years ago, the first nanosized 
colloidal gold particles in fact, were prepared by Michael 
Faraday. This discovery at the early time served as a precur-
sor for the development and advancement of drug delivery 
system. In 1994, the first report regarding surface modified 
liposome nanoparticles for sustained circulation was de-
scribed [4]. Nanomaterials are often defined as materials or 
structures in the nanometer size range less than 100nm ac-
cording to National Nanotechnology Institute [5]. Some have 
defined nanomateial as materials with boarder range of 
nanosize scale in 1-1000nm [6]. 
 In 1990s, the discoveries of nanosized devices such as 
nanowire, nanosensor and quantum dot bioconjugate were 
successively described [7-9]. Very recently, fabrication of 
drug delivery system in nanosized by ink-jet printing has 
also been reported [10]. Indeed, there seems a never ending 
reporting of new development of “nano” devices everyday. 
What initiated this recent excitement over the magic of 
nanotechnology? The attraction of nanoparticles appears to 
stem from their unique physical, chemical and maybe even 
biological characteristics, including nanosize, large surface/ 
volume ratio and capability in encapsulation for a wide vari-
ety of drugs. For example, the small size can be useful in 
overcoming biological and biomedical barrier, easily enter 
the cells and organelles and can interact with intraceullar 
proteins as most cells are only 10-20m in size. In this re-
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spect, the framework of nano periodic table was announced 
only very recently in 2009 in the NSF nanoscale science and 
engineering meeting [11]. 
 All together, the ultimate goal of using nanotechnology is 
to develop an effective drug delivery device with pro-
grammed functions. The history of nanomedicine evolution 
reveals the promise of nanotechnology in the development of 
drug delivery systems to overcome the existing challenges in 
cancer therapy. 
CHALLENGES IN CANCER DRUG THERAPY 
 The clinical outcome of treatment with many anticancer 
drugs has not been met with universal success as hoped. The 
major hurdle of current anticancer drugs is to kill tumor cells 
specifically without significant side effects. The theoretical 
basis on which existing anticancer drugs exert their effects, 
relies on the higher mitotic rate in the tumor cells than that of 
normal cells. This often results in high systemic toxicity and 
the therapeutic window is narrow. Repeated dosage is thus 
limited. The concept of specific targeting has emerged and is 
crucial to help reduce uptake by normal tissue and increase 
the payload of the drug inside the tumor. Furthermore, as 
more than 40% of anticancer drug is poorly soluble in aque-
ous environment, the ultimate bioavailability and therapeutic 
efficiency can be significantly hampered. Conventionally, 
solvents and emulsifiers have been used to dissolve poorly 
water soluble anticancer drugs. They are suggested to be 
potentially carcinogenic [12] and can be toxic to liver and 
nervous system [13].
a) Tumor Barrier 
 Understanding the cancer structure is paramount to over-
coming the challenges in the design of the drug delivery sys-
tem. Cancer has a unique architecture characterized by vas-
cular pores, heterogeneous vasculature and increased blood 
supply. Tumor tissues are characterized with disorganized 
and leaky tumor vasculature with heterogeneous gaps and 
pores (ranging from 200-800nm). This allows macromole-
cules up to 400-500nm leaving the vascular bed and accumu-
lating inside the interstitial space in tumor. Together with 
poor lymphatic drainage, this contributes to the significant 
retention of marcomolecules, which is known as the en-
hanced permeation and retention (EPR) effect [14]. Besides 
the defective vascular architecture, the high vascular density 
keeps blood supply for tumor growth. This supports enor-
mous amount of tumor tissue growth, move than in normal 
state. Thus, a major principle of cancer chemotherapy is to 
block, or to reduce tumor angiogenesis. Another action 
would be to induce apoptosis of growing tumor cells. Mean-
while, delivery of the therapeutic agents systemically is often 
compromised by the body’s normal physiology, including 
hepatic and renal clearance, uptake by RES (reticuloendothe-
lial system) organs, degradation by enzymes as well as by 
endosome/lysosome, resulting in less dose level to the tumor 
cells. 
 The physiological barrier depends partially upon the size 
of nanoparticle carriers, in which particle size can determine 
the clearance kinetics of these nanoparticles. It has largely 
been reported that the ideal size of nanoparticle for cancer 
treatment lies between 70-200nm [15, 16]. The size of 
nanoparticle smaller than 10 nm is rapidly eliminated by 
kidney clearance. On the other hand, those bigger than 200 
nm are primarily taken up by the RES system, such as 
Kupffer cells in the liver and spleen [17]. Further entrapment 
of the nanoparticles escaping from circulation is effected by 
fenestra and sinusoids in liver and spleen [18-20] if the parti-
cle size is bigger than the pore size of fenestra or sinusoids 
(up to 150nm) [21, 22]. Particle size can also determine the 
efficiency of tumor uptake. In addition to the lower size 
limit, due to the unique feature of the leaky vasculature in 
tumors, known as EPR (enhanced permeability and reten-
tion) effect, 400-500 nm is upper size limit for the extravasa-
tion of nanoparticle carrier into tumor tissue. The size 
growth of nanoparticle can occur by aggregation. Small par-
ticles have larger surface area and higher particle number 
than bigger particles at the same mass concentration. Thus, 
extremely small nanoparticles (diameter  3nm) could not be 
easily stabilized and aggregated rapidly [23]. This could be 
detrimental in blood circulation and may result in blockage 
of the capillaries. Considering the ability to pass through the 
capillaries, the nanoparticle size without aggregation is more 
possible to prevent thromboembolism compared to micropar-
ticle size and thus can be beneficial for systemic delivery. 
Surface characteristics can control the extent of particle ag-
gregation at interstitial sites. For example, hydrophilic 
nanoparticles are more likely to interact poorly with ground 
substances at interstitial sites. 
b) Blood Brain Barrier (BBB)
 The blood brain barrier is formed by tight intracellular 
gap junctions of endothelial cells and high density of cells 
filtering against the entry of molecules into the cerebrospinal 
fluid. Only 5% of current drugs can pass through the BBB 
and affect the CNS. It is challenging even for any drug in the 
nanosized range to permeate through the BBB. Reports have 
demonstrated that both size and hydrophobicity represent the 
major components in determining the crossing of the BBB 
and thus are both crucial in the design of “nano” drugs for 
CNS delivery [24, 25]. For example, small molecule hista-
mine (~100 Da, ~0.01nm) is not able to pass through the 
BBB due to highly dense hydrophilic hydrogen-bonded end 
groups [26]. Apparently, drugs that are lipid soluble with 
molecular size range between 400-600Da can pass through 
the BBB. However, the tight gap junction at the BBB can 
prevent the crossing of even very hydrophobic molecules 
[27, 28]. 
c) Systemic Toxicity 
 The dosage of systemic delivery of drugs can be re-
stricted by the systemic toxicity. This is particularly true in 
cancer drug delivery since most of the cancer therapeutics is 
highly toxic. Depending upon the route of administration and 
site of application, systemic toxicity varies. One way of re-
ducing this is by local delivery, as a high concentration of 
drugs can be achieved and stays at the local tissue, with re-
sulting lower systemic toxicity. 
 In the circulation, systemically administered cancer drugs 
have higher chance to interact with and be taken up by RES 
organs, kidney, marrow and central nervous system, result-
ing in the apoptosis of healthy cells. A nanoparticle carrier 
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system can minimize systemic uptake is thus crucial for re-
ducing systemic toxicity and more effective cancer therapy. 
d) The Mode of Drug Delivery 
 The route of administration can affect the delivery of 
nanoparticle and thus the availability of encapsulated drug at 
the action site. Oral administration of nanoparticle drugs has 
to first pass through the stomach. Since absorption occurs in 
stomach and largely in intestine [29], strategies have been 
employed to resist premature acid degradation in the stom-
ach (pH~2.5) [30]. For local tumor delivery in GI tract, some 
nanoparticle carriers have been designed to use the unique 
pH environment in GI tract to control the drug availability. It 
has been reported that pH sensitive nanoparticles can trigger 
the release of the encapsulated drug in response to the local 
pH stimuli, resulting in inhibiting tumor growth locally in 
the GI tract [31]. On the other hand, some oral drugs have 
been used to treat tumor in systemic organs. In this case, it 
may be advantageous to design a carrier system resistant to 
liver metabolism in addition to the pH sensitive feature, 
since many oral drugs have to go through first pass metabo-
lism in the liver after absorption. A common mode of deliv-
ery for cancer treatment is the intravenous (i.v) route admini-
stration which allows the nanoparticle directly going into the 
bloodstream. Delivery into the tumor destination via the sys-
temic route is considerably more challenging than local ad-
ministration since drugs will be distributed widely in sys-
temic organs such as heart, brain, liver, kidney and RES or-
gans. In this case, drugs in blood circulation will have more 
interaction with the systemic organs which may increase the 
chance for rapid clearance by kidney and RES organs. The 
extent of tissue distribution can be affected by membrane 
permeability, the blood supply and the binding of drugs to 
specific targeted tissue (i.e. tumors). To induce the preferen-
tial distribution in tumors via systemic administration, cur-
rent nanotechnology has been used to design nanoparticle 
carrier with size and surface chemistry for improving the cell 
uptake and binding inside tumor [32, 33]. 
ROLE OF NANOTECHNOLOGY IN DRUG DELIV-
ERY 
 The importance of the nanoparticles in drug delivery is 
due to multifactorial features, including the size, structure, 
encapsulation efficiency, release characteristics and the ca-
pability to constitute surface modification. The extremely 
small size of nanoparticles gives a high surface/volume ratio 
for better membrane uptake of drug. The nanoparticle carrier 
can be a good nanotechnology platform to improve the drug 
efficacy and tumor targeting. An example is the liposomal 
encapsulation system, which has shown promise in drug de-
livery by displaying an enhanced binding to the tumor endo-
thelial cells and intracellular uptake through endocytosis [34, 
35]. A new generation of liposome encapsulation system is 
developed by combining physical or chemical modification. 
The physical modification of liposome carrier platform with 
local ultrasound enhances the tumor site-specific therapeutic 
efficiency [36, 37]. However, one shortcoming of this physi-
cal approach is that healthy tissue cannot be protected, and 
bystander damage is also seen [38]. An alternative is chemi-
cally modified liposome and has been described to improve 
the systemic stability and tumor specificity [39]. Further-
more, the use of nanoparticle carrier can develop in drug 
encapsulation as a drug reservoir system. Utilization of in-
herent biodegradable nanomaterial such as a composite of 
liposome and polymer can sustain the drug release in a con-
trolled and regulated manner [40]. Multiple layer of 
liposome has also been suggested to control the release in a 
prolonged period of time [41]. This design is favorable to the 
development of a clinically useful system since the effective 
dose at therapeutic range can last for an extended period of 
time. 
 This is particularly useful if the anticancer drug requires 
systemic delivery, as it is difficult for sufficient nanoparticle 
carrier to bypass the physiological, tumor and even in case of 
brain tumor blood brain barriers and finally reach the tumor 
destination. 
 An ideal nanoparticle drug carrier should be able to direct 
the drug payload into tumor and the entire drug should re-
lease locally within the tumor environment. This would be 
beneficial to reduce systemic toxicity and enhance the effi-
ciency of cancer therapeutics. But the current development 
and design is not perfect yet. To design an ideal drug deliv-
ery system for cancer therapy, there are four criteria: (1) The 
nanopaticle carrier should be biodegradable and biocompati-
ble in considering the safety concerns (2) The nanoparticle 
carrier should be stable in the circulation. (3) The accumula-
tion of nanoparticle carrier should be preferential and effi-
cient in the tumor (4) The drug should release efficiently and 
remain within the tumortissue structure.
 The following will describe several significant merits of 
nanotechnology development in drug delivery: 
a) Basic Nano Systems 
Lipid/Polymer Nanoparticles 
 Lipid or polymer nanoparticles provide significant con-
tribution in the strategy to improve therapeutic properties of 
drugs [42]. Considerable efforts have been attempted to 
complex cationic lipids and/or polymers with plasmid, DNA 
or siRNA for antitumor therapy application [43]. Further-
more, numerous drug delivery systems such as liposomes, 
nanospheres and polymeric nanocarrier, if adsorbed or cova-
lently binded with protein antigens, can be a strong adjuvant 
to phagocytic cells [44-46]. Positively charged lipid based 
carrier are known to trigger strong immune response when 
injected into the body. Positively charged liposomes are 
more able to induce the antigen specific Th1 type immune 
response [47, 48] when compared with neutral or negatively 
charged liposome. This explains the recent trend in the use of 
liposome as an immunoadjuvant against cancer. Nonetheless, 
this can be problematic when it is injected systemically due 
to the possible uptake of highly toxic anti-cancer drug by T 
cells and resulting in the killing of these T cells. 
 Rapid clearance of drugs from the circulatory system by 
phagocytic cells is common. Major phagocytic cells like 
macrophages and dendritic cells are well known in playing 
key roles in initiating and generating the immune response 
[49]. Opsonization is one predominant mechanism (a surface 
deposition of nonspecific opsonic factors in blood such as 
fibronectin, immunoglobins and complement proteins) to aid 
and trigger the recognition by macrophages and dendritic 
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cells via complement activation when the drug is injected 
systemically [49, 50]. By activating complement system, the 
positively charged nanoparticle carrier facilitates clearance 
from blood by the Kupffer cells of RES organs [51]. Besides 
surface charge, particle size is another predominant factor to 
determine the extent of immune response, in which the ex-
tent of opsonization decreases when the size of liposome 
decreases [52]. Nonetheless, positively charged lipid based 
nanoparticle can still be a promising option in cancer therapy 
since it facilitates the binding and uptake by the tumor cells, 
resulting in increased therapeutic efficiency and anti-tumor 
activity [53, 54]. Positive charge is often shielded in case of 
designing a long circulating carrier that is potentially useful 
for systemic administration. As blood circulates through 
RES organs more than the tumor, there is a higher possibility 
for the nanoparticle to interact with RES organs. If the posi-
tive charge on nanoparticle surface is not protected, RES 
organs will take up significant amount of nanoparticles. 
Thus, surface engineering of liposomes has been attempted 
to shield the charged surface using pegylation (conjugation 
of Poly(ethylene) glycol, abbreviated as PEG). This ap-
proach can enable reduced opsonization and thus the RES 
uptake. 
 In the case where a large portion of new drug candidate is 
poorly water soluble, leading to reduced development poten-
tial because of low drug bioavailability, one option to en-
hance the drug bioavailability is nanosuspension. This is the 
colloidal dispersion of drugs. Nanosuspension has been re-
ported to be useful for drugs that are not soluble in both 
aqueous and oil phase. For drugs that are poorly soluble in 
water but highly soluble in oil, oil in water microemulsion is 
an alternative. Lipidic nanoparticle carrier composed of 
emulsifying wax with surfactant stabilizer Brij has been re-
ported to encapsulate successfully a wide range of lipophillic 
drugs [55-57]. It has demonstrated high encapsulation effi-
ciency (>95%) of lipophillic drugs. This means that high 
loading of lipophillic drug can be achieved by the formula-
tion. It is highly stable and compatible with blood. Our pre-
clinical study in neuroblastoma bearing model showed that 
the lipidic carrier is able to reduce toxicity and enhance the 
anti-tumor activity [58].
Polymeric Micelles
 Polymeric micelles are formed in aqueous solution as 
core shell structures and often composed of block copolymer 
with hydrophobic and hydrophilic components. The hydro-
phobic core serves as a reservoir for hydrophobic drugs and 
the hydrophilic shell reduces opsonization and subsequent 
rapid clearance. This allows the water insoluble drugs to be 
entrapped in the core for solubility. The features of nanosize, 
easy manipulation of surface chemistry make them suitable 
as nanoparticle carriers. Change of polymer block composi-
tion to form complex with polycationic polymer such as 
poly(L-lysine) or polyaspartamide derivative, poly{N-[N-(2-
aminoethyl)-2-aminoethyl]aspartamide} (PAsp(DET)) has 
developed as a carrier to deliver a wide variety of siRNA and 
plasmid DNA for antiangiogenic gene therapy [59, 60]. Effi-
cient in vivo and in vitro gene delivery in tumors has been 
observed using the polyplex micelles [61]. Surface modifica-
tion of the polyplex micelles with RGD ligands has also 
shown improved intracellular trafficking [62].
Gold Nanoparticles 
 Gold nanoparticles have commonly been used as 
nanosized diagnostic and therapeutic agents. Due to the 
unique chemical structure, the use of colloid gold has shown 
promise in drug delivery. Gold nanoparticles functionalized 
with citrate [63, 64] and transferrin [65] played a vital role in 
facilitating cellular internalization. Recent study of the cit-
rate conjugated gold nanoparticle determined how the size of 
nanoparticles could influence the ability of cellular internali-
zation. By using induced coupled-plasma atomic emission 
spectroscopy (ICP-AES), it was found that the particle size 
of citrate conjugated gold nanoparticles around 50nm are 
mostly internalized by HeLa cells (in a size range of 14-100 
nm) [66]. Our lab routinely determines the tissue distribution 
in different organs of gold nanoparticle compounds using 
induced coupled plasma- mass spectroscopy (ICP-MS). 
 Gold composites have further been explored as “nanobul-
lets” and “nanobombs” for killing cancer. Laser induced 
explosion of the light absorbing gold nanoparticles at local 
tumor site was reported to kill cancer cells [67]. The hollow 
gold nanoparticles can be developed as targeted anti-cancer 
drug carrier by decorating the surface with targeting mole-
cules. After homing to the tumor site, the cancer cells are 
“cooked” by laser irradiation [67, 68]. Further, this system 
can be a dual functional delivery system as a control drug 
release carrier and a photothermal ablation mediator when 
doxorubicin was coated on the inner and outer surface of 
hollow gold nanoparticles. The near-infrared irradiation was 
used to mediate both the release of doxorubicin and pho-
tothermal ablation of cancer cells [69]. 
 Effort has been made to entrap gold nanoparticles into a 
lipidic carrier to enhance the potential in antitumor applica-
tion. Gold porphyrin has been documented as a very potent 
antitumor drug [70]. We complexed a lipidic nanoparticle 
carrier with gold porphyrin and demonstrated a reduced sys-
temic toxicity and enhanced the tumor uptake [58].
Dendrimers 
 Dendrimer are highly branched synthetic polymers first 
invented by Tomalia in early 1980s [71]. It consists of center 
core, integral region and numerous functional end groups. 
The growth of polymer occurs in outward direction from 
central core by stepwise polymerization. It is characterized 
with numerous cavities in the core structure creating chan-
nels and cages. Precise control of size can be achieved by the 
extent of polymerization. The intracellular uptake of den-
drimer by receptor mediated endocytosis can be aided using 
the conjugation of biotin [72]. Dendrimers contribute to drug 
delivery either by binding the drug on the periphery as pro-
drug or entrapping the drug in the center core. Recent pro-
gress has been made to dendrimer formulary as a biocom-
patible drug carrier for cancer targeting therapy. Surface of 
dendrimer enables the coating with poly(ethylene) glycol 
(PEG) or targeting ligand for folate receptors and showed 
potential in improved cellular targeting for cancer therapy 
[73,74].
Carbon Nanotubes (Naked and Functionalized) 
 Carbon nanotubes consist of graphite sheets rolled up 
into tubes and belong to the fullerene family. They can be 
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single walled or multi-walled nanotubes. The size and di-
ameter varies between the two structures. The single-walled 
has the diameter of 0.5-3nm and length of 20-1000nm while 
the multi-walled comprising of multiple layer has the diame-
ter of 1.5-100nm and length of 1-50m [75] with interlayer 
spacing of approximately 0.34 nm [76]. They are considered 
as inert and hydrophobic nanomaterials. Carbon nanotubes 
exhibit a unique feature of thermal, electric and mechanical 
properties. They can absorb energy through irradiation, mag-
netic field or near-infrared and transform the energy into 
heat. Surface functionalization with acetate nanocomposites 
can provide ways to resist better thermal degradation and 
demonstrated better thermal stability [77]. To improve the 
water solubility, surface functionalization with water soluble 
ethylene glycol or PEG has been explored [78]. Nonetheless, 
carbon nanotubes could be associated with internal tissue 
damage and subsequent development of mesothelioma, 
which currently remain major concerns of the FDA [79].
Modification for Drug Delivery System-Poly(Ethylene) 
Glycol (PEG) 
 PEG first emerged in the early 90s for surface modifica-
tion of liposomes. Due to the neutral charge and inert fea-
ture, PEG reduces opsonization and stabilizes the nanoparti-
cle carrier by adding steric barrier. Surface modification of 
nanoparticles using PEG (known as pegylation) is often re-
ferred as “stealth”, as they are more able to escape the sur-
veillance of the RES organs and thus have prolonged circu-
lating time in blood. However, too much PEG insertion can 
be disadvantageous. This has been shown in the case of 
doxorubicin where excessive peglylation hinders the uptake 
of drug by the tumor cells by reducing the binding on the 
cells [80]. 
 Pegylated nanoparticles are able to enhance preferential 
uptake into the tumor. The nanoparticles can be uptaken by 
passive targeting via diffusion across the leaky blood vascu-
lature. RES competes with the tumor for the uptake of 
nanoparticle. Thus the longer stay in the blood circulation 
allows higher chance of the nanoparticle getting into the tu-
mor tissue. 
b) “Smart” Drug Delivery System 
 Novel nanotechnology serves as platform in the design of 
smart drug delivery system. Smart drug delivery system aims 
to further improve drug delivery efficiency by (1) additional 
triggering the controlled release in response to local envi-
ronmental stimuli (2) specific targeting of tumor tissue 
and/or (3) prolonging the circulation time. 
Heat Sensitive Nanoparticle Carriers 
 The first report of controlled release drug delivery system 
was described by Dominici and Macroni in 1965 [81]. Heat 
sensitive or pH sensitive nanoparticle carrier has been de-
signed to control release of the drug. The early effort in the 
design of temperature sensitive drug carriers was mainly 
focused on developing injectable and a controlled release 
drug carrier. Thermosensitve polymer has gained a lot of 
interest in drug delivery since it has demonstrated prolonged 
and better control of drug release. The block (diblock, tri-
block, multiblock) copolymer consisting of biodegradable 
polyesters and PEG demonstrate controlled biodegradability 
and good biocompatibility. For example, PEG-PLGA-PEG 
can form polymeric micelle and induce micelle growth at 
body temperature and serve as drug reservoir [82]. At body 
temperature, the polymeric micelle can release the drug by 
surface or bulk degradation over time or diffusion via po-
lymeric matrix [83]. Acidic environment or high water con-
tent within the polymer triggers the degradation [83]. The 
composition and molecular weight also determines the deg-
radation rate [84]. In past decades in drug delivery, tumor 
targeting was one important issue as it could provide one 
potential solution for reducing the systemic toxicity of can-
cer drugs and improving the therapeutic efficiency. Recent 
efforts have attempted to develop thermosensitive nanoparti-
cle carrier for tumor targeting [85-87] after systemic admini-
stration. Nakayama et al has designed polymer consisting of 
hydrophobic block and a thermo-responsive poly(N-
isopropylacrylamide–N,N-dimethylacrylamide) (PNIPAAm–
PDMAAm) hydrophilic block [88]. This block copolymer 
has lower critical solution temperature (LCST) at around 
40°C [88]. Rapid drug release was observed in response to 
the thermal stimuli by local tumor heating to or above the 
LCST temperature [88]. Local heat is produced by the inser-
tion of hyperthermia applicator within tumor [89]. However, 
the applicator is best used for tumors at abdomen, pelvis and 
extremities possibly due to the ease of applicator accessibil-
ity to the tumor and insufficient heating effect at deeper tis-
sue. Another exciting approach is to functionalize the 
nanoparticle carrier with magnetite (Fe3O4) for magnetic 
targeting and controlled release the drug locally in tumor site 
triggered by pH and heat [85].
pH Sensitive Nanoparticle Carriers 
 The pH sensitive drug delivery system uses the change in 
pH in the intra-cellular compartment to switch on the drug 
release. The carriers are often biodegradable liposomes, 
polymers or hydrogels. The therapeutic drug release can be 
triggered by swelling in the lysosomal environment or by the 
acidic or alkali catalyzed hydrolysis degradation, resulting in 
the entrapped drug payload into the cytosol. The pH sensi-
tive liposome containing PHC (lipid palmotyl homocysteine) 
has long been proposed as a useful application for targeting 
drug delivery in a region that is slightly below the physio-
logical pH (between pH 6 to pH 7.4) such as tumor, inflam-
matory and infection sites [86]. The pH sensitive polymer 
has also been developed for the escape of the intracellular 
barrier. Liposome coated or complexed with proton sponge 
Polyethyleneimine (abbreviated as PEI) enters the acidic 
lysosome/endosome compartment via endocytosis. The 
amino group is able to sequester protons and trigger the entry 
of chloride ions and water molecule into the lysosome/ en-
dosome compartment, leading to swelling and the eventual 
rupture of the lysosome/endosome. Recently, long circulat-
ing and biodegradable pH sensitive polymeric nanoparticle 
carrier composing of sulfonamide was made which could 
respond to even sharper pH changes (between pH 6.6 to pH 
7.4 normal blood pH) [64]. This design is characterized with 
shielding of polymeric nanocarrier by cell penetrating pep-
tide TAT peptide at physiological pH, and unshielding at 
around or below pH 6.8 by detachment of TAT peptide. An-
other example is the formation of nanoparticles by direct 
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conjugation of cisplatin with hydrophobic segment of di-
block polymers via hydrozone bond. The cleavage of the 
hydrozone bond mediates the sharp response of drug release 
corresponding to slight change of environment acidity [90]. 
 One concern of this is that the encapsulated drug has to 
be released at the free drug level to reach the therapeutic 
dose. Indeed, the carrier can be collapsed by the pH gradient 
in acidic environment such as lysosome/ endosome com-
partment and releases the drug in a controlled manner. In 
addition, the rate of drug release from pH sensitive carrier 
also depends on the encapsulation method and drug types. 
For example, cisplatin entrapped in the liposome showed 
minimal antitumor activity despite the accumulation in the 
tumor tissue [91] while encapsulated doxorubicin in 
liposome demonstrates antitumor activity [92].
Antibody Conjugated Nanoparticle Carrier 
 Free cancer therapeutics or nanocarrier constitute a plat-
form for conjugating with monoclonal antibody that is spe-
cific to antigen expressing on the tumor cells or tumor endo-
thelial cells. A variety of antibodies and growth factor recep-
tors, such as nerve growth factor (NGF), vascular endothelial 
growth factor (VEGF) and epidermal growth factor (EGF)
[93-98], which are overexpressed in the tumor have been 
used to improve cancer drug delivery specificity. It can also 
reduce the systemic toxicity since the antibody conjugates 
can be developed to shield the free anti-cancer drugs. The 
solubility is further enhanced due to the hydrophilic nature of 
the antibody. An example of this is Taxane conjugate, an 
antibody conjugate with Paciltaxol. It has been reported to 
enhance the solubility and tumor targeting drug delivery 
[99].
Magnetic Directed Drug Delivery System 
 Magnetic nanoparticles and magnetic nanoparticle carri-
ers including liposomes and dendrimers have been developed 
for cancer drug delivery. The carriers are made either by 
encapsulating drugs in the magnetic nanoparticles or as a 
composite with the magnetic nanoparticle carrier. The use of 
magnetic nanoparticle carrier has been developed to direct 
drug delivery to the tumor site. One way of magnetically 
directed cancer drug delivery is by locally applying magnetic 
field at the tumor target site using MRI (magnetic resonance 
imaging). The approach should be feasible in most tumor 
sites since the magnetic field strength of MRI is sufficient 
enough to apply to most soft tissue and mineralized tissue. 
The magnets are often iron oxides or gadolinium containing 
nanoparticles. The magnet can be either surface bound or 
encapsulated into the nanoparticles. If the magnet is bound 
on the surface of the carrier rather than being entrapped in 
the carrier, it will increase the systemic overexposure to 
gadolinium. Overexposure to gadolinium increases the risk 
of systemic toxicity associated with more tissue and blood 
vessel deposition. Another way in magnetic drug targeting is 
to complex with pH sensitive polymeric matrix carrier and 
this has been suggested to be useful in the acidic gastrointes-
tinal tract environment [100]. Targeting diagnostic system
based on magnetic nanoparticle can be used to identify the 
location of the tumor by functionalizing with ligand binding 
specifically to the tumor receptor. 
CURRENT STATUS OF NANODRUG THERAPY 
 There are currently several nanodrugs available in the 
market for cancer treatment such as Doxil®, Abraxane®.
Doxil® is liposomal encapsulated doxorubicin. With the so 
called stealth liposome using pegylation, dose frequency can 
be minimized, resulting in a longer treatment cycle repeated 
every 4 weeks. Due to the long circulating feature, the 
doxorubicin encapsulated in stealth liposome demonstrated 
more favorable pharmacokinetic. Clearance and volume of 
distribution decrease by at least 250 fold compared with free 
doxorubicin [101]. Clinical study also shows that it is associ-
ated with modest toxicity and side effects in patients [102]. 
However, targeting strategy could further be improved. This 
may be done effectively by using active targeting, for exam-
ple conjugation with tumor specific antibody or ligands re-
sulting a tumor receptor mediated internalization.
TARGETING CANCER STEM CELLS: THE NEXT 
STEP 
 In recent years, cancer stem cells have received tremen-
dous attention. Increasing evidence have showed that cancer 
stem cells can initiate and sustaining tumor growth and can 
be associated with tumor recurrence [103, 104]. Recent work 
has also suggested that cancer stem cells could be responsi-
ble for cancer drug resistance [105]. Identification of their 
location and targeting them will require novel therapeutic 
design in cancer treatment [106]. 
FUTURE HORIZONS 
 The ideal drug delivery system needs to enhance the effi-
ciency of delivery and payload of the drug specifically in the 
tumor. These depend upon the accumulation, retention and 
release of the drug in the tumor tissue. The conjugation with 
PEG as described previously is one promising option to in-
crease the uptake by the tumor over the RES. The conjuga-
tion of ligand to tumor specific receptor such as EGFR is an 
active targeting strategy that can increase binding to the tu-
mor cells. Thus the retention and the intracellular uptake of 
the drug can further be improved. Thus, the approach of 
combining conjugation of both PEG and tumor specific 
ligands can potentially further increase the accumulation as 
well the bioavailability of drug in the tumor. More work in 
development is currently underway. 
 Given that nanoparticle carrier get into the tumor and 
perform effective anti-tumor activity, it is important to de-
velop an non-invasive in situ detection for investigating tu-
mor recurrence and tracking the location of metastasized 
tumor cells. For example, the carrier that can deliver the anti-
tumor drug but also covered with particles for tumor surveil-
lance and imaging would be ideal. If the drug demonstrates 
good imaging potential, it would be possible to combine the 
therapeutic and diagnostic approaches in the same nanoparti-
cle carrier. Thus, “theragnostics” (therapeutic + diagnostic) 
may carry the next potential in nanomedicine development 
for cancer. 
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